• Molecular NameSelegiline
  • SynonymL-Deprenalin; Selegeline Hcl; Selegilina [INN-Spanish]; selegiline; Selegilinum [INN-Latin]
  • Weight187.286
  • Drugbank_IDDB01037
  • ACS_NO14611-51-9
  • Show 3D model
  • LogP (experiment)2.9
  • LogP (predicted, AB/LogP v2.0)2.86
  • pkaN/A
  • LogD (pH=7, predicted)2.62
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.8
  • LogSw (predicted, AB/LogsW2.0)2.24
  • Sw (mg/ml) (predicted, ACD/Labs)0.68
  • No.of HBond Donors0
  • No.of HBond Acceptors1
  • No.of Rotatable Bonds5
  • TPSA3.24
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug used for the treatment of early-stage Parkinson's disease, depression and senile dementia.
  • Absorption_value100.0
  • Absorption (description)Rapidly absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • Bioavailability4.4
  • Protein binding94.0
  • Volume of distribution (VD)1.9 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensive first-pass metabolism. Desmethylselegiline is metabolized by CYP2C19.
  • Half life1.9 h
  • Excretionurine
  • Urinary ExcretionNegligible
  • Clerance1500 ml/min/kg
  • ToxicityLD50=63 mg/kg (rats, IV)
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=400 (ip)